Idgie Health review
This seller calls its own microdosing approach off-label on the page that sells it, which few in this category do.
The verdict
Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an oral semaglutide tablet at $287. Its own product copy describes microdosing as an off-label approach rather than leaving the reader to work that out.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Dose pricing
- Flat across doses
- States
- 50
- Injection
- From $134/mo
- Oral
- From $287/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Idgie Health sells compounded semaglutide and compounded tirzepatide as microdose injections, and semaglutide as an orally dissolving tablet. The three figures read $134, $179 and $287 a month on September 11, 2026. Each is billed monthly and described as flexible. Three-month purchases were $377, $497 and $747 charged on the day of order.
Who writes the prescription, and what do they see?
A prescription is required and the plans are sold as month-to-month with a three-month alternative. The tablet is listed on the program menu as a semaglutide and ondansetron combination, which names a second active ingredient rather than implying one. What an intake asks before a prescription is issued is not published. Coverage is published as fifty states.
Treatment is arranged remotely and the products are described by dose class rather than by milligram. Microdosing means a weekly dose below the maintenance doses the approved labels set out. The ondansetron in the tablet is an antiemetic, included against the nausea that accompanies these molecules. Whether it reduces that nausea at the quantity used was not measured in the outcome trials.
What happens when the dose goes up?
The published figure is one rate for the microdose product rather than a ladder. A reader who escalates past the microdose range is buying a different product rather than a higher tier of this one. What the next rung costs is not published beside these three. The three-month purchases are charged in full on the day they are placed.
What the price includes
The monthly and the three-month routes are both published, which lets a reader see the whole choice. Semaglutide runs $134 monthly against $125 a month across three, and tirzepatide $179 against $165. The tablet is the expensive route at $287 monthly, or $249 a month across three. Every three-month figure is a single charge rather than a lower monthly bill.
What it claims, and what it cites
All three products are compounded, so a pharmacy prepares them and no regulator reviews the finished dose form. Naming microdosing as off-label is accurate and unusual to print. The published weight-change results for semaglutide and tirzepatide came from label doses over sixty-eight and seventy-two weeks. What a microdose produces over the same period was not measured.
Where it holds up, and where it does not
- Strength: Seller names microdosing as off-label
- Strength: Monthly and three-month figures both published
- Strength: Second active ingredient named on the tablet
- Limitation: Microdoses sit below the studied doses
- Limitation: Three-month price is charged in full
- Limitation: Tablet costs more than either injection
What the evidence says about this kind of treatment
The assessment above is about Idgie Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one.
- Wrong for
- A reader looking for the doses the outcome trials used, since every product priced here is a microdose or a tablet rather than a label-dose injection.
How Idgie Health compares
| Seller | Who it suits | Go |
|---|---|---|
| Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | See Bayan Health → |
 Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | See Enhance MD → |
| Lean Meds | A reader deciding between paying month to month and committing a year up front, because both rungs are published side by side. | See Lean Meds → |
More GLP-1 telehealth sellers reviews: EmbodyEverSlimFidelity Medical ClinicHarper MedsKERNX HealthLiberty
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- What does off-label mean on this page?
- It means the dose is used in a way the approved label does not describe. Idgie Health applies the phrase to its own microdosing approach, on the page that sells it.
- Why is the tablet dearer than the injection?
- The tablet is $287 a month against $134 for the microdose injection. It is listed as a semaglutide and ondansetron combination, which is a different preparation rather than the same drug in another form.
- Is the three-month price a lower monthly rate?
- No. $377 is charged on the day of order and works out at $125 a month. The monthly plan bills $134 at a time and can be stopped sooner.
- Is Idgie Health expensive compared with other GLP-1 telehealth sellers?
- Idgie Health publishes a starting figure of $134/mo. Across the 32 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $139, which puts Idgie Health below the median, toward the cheaper end. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.